Local anesthetics noncompetitively inhibit function of four distinct nicotinic acetylcholine receptor subtypes.
Local anesthetics (LAs) are considered to act primarily by inhibiting voltage-gated Na(+) channels. However, LAs also are pharmacologically active at other ion channels including nicotinic acetylcholine receptors (nAChR). nAChR exist as a family of diverse subtypes, each of which has a unique pharmacological profile. The current studies established effects of LAs on function of four human nAChR subtypes: naturally expressed muscle-type (alpha1*-nAChR) or autonomic (alpha3beta4*-nAChR) nAChR, or heterologously expressed nAChR containing alpha4 with either beta2- or beta4-subunits (alpha4beta2- or alpha4beta4-nAChR). Of the LAs tested, those with structures containing two separated aromatic rings (e.g., proadifen and adiphenine) had the greatest inhibition potency (IC(50) values between 0.34 and 6.3 microM) but lowest selectivity (approximately 4-fold) across the four nAChR subtypes examined. From the fused, two-ring (isoquinoline backbone) class of LAs, dimethisoquin had comparatively moderate inhibition potency (IC(50) values between 2.4 and 61 microM) and approximately 30-fold selectivity across nAChR subtypes. Lidocaine, a commonly used LA from the single ring category of LAs, blocked nAChR function with IC(50) values of between 52 and 250 microM and had only approximately 5-fold selectivity across nAChR subtypes. Its quaternary triethyl ammonium analog, QX-314, had greater inhibition potency, but the trimethyl ammonium derivative, QX-222, was the least potent LA at all but the alpha4beta2-nAChR subtype. With only a few exceptions, LA effects were consistent with noncompetitive inhibition of nAChR function and occurred at therapeutic doses. These studies suggest structural determinants for LA action at diverse nAChR subtypes and that nAChR likely are clinically relevant targets of LAs.
Gentry
C L
CL
Division of Neurobiology, Barrow Neurological Institute, Phoenix, Arizona 85013, USA.
Lukas
R J
RJ
D000779:Anesthetics, Local / Q000494:pharmacology*; D002460:Cell Line; D018680:Cholinergic Antagonists / Q000494:pharmacology*; D006801:Humans; D007546:Isoquinolines / Q000494:pharmacology; D011335:Proadifen / Q000494:pharmacology; D011343:Procaine / Q000494:pharmacology; D011978:Receptors, Nicotinic / Q000145:classification / Q000187:drug effects / Q000378:metabolism*; D013748:Tetracaine / Q000494:pharmacology
D000779:Anesthetics, Local; D018680:Cholinergic Antagonists; D007546:Isoquinolines; D011978:Receptors, Nicotinic; D013748:Tetracaine; D011343:Procaine; C009146:dimethisoquin; D011335:Proadifen